GHRP-2 and GHRP-6: Two Hexapeptides, Two Different Profiles

The growth hormone releasing peptides are worth understanding as a group before either member is examined individually, because their history explains an oddity that confuses people coming to this literature: a receptor named after synthetic drugs, discovered more than a decade before anyone found the hormone that naturally binds it.

An accident of opioid chemistry

The line of research that produced these compounds did not set out to find growth hormone releasers. It began with enkephalins, the endogenous opioid peptides, and with efforts to make synthetic analogues of them. Some of those analogues turned out to release growth hormone from pituitary tissue, and to do so through a route that did not involve the growth hormone releasing hormone receptor 2.

That observation was pursued systematically. A structure-activity programme through the early 1980s produced progressively more potent compounds, culminating in a hexapeptide reported in 1984 that released growth hormone specifically and with good potency in both cell culture and animals 1. This compound became known as GHRP-6.

The finding created a puzzle that took twelve years to resolve. These peptides plainly bound something in the pituitary and hypothalamus, and that something was not the GHRH receptor. In 1996 the target was cloned and named the growth hormone secretagogue receptor 3. Three years after that, ghrelin was isolated from stomach tissue and identified as the receptor's natural ligand 5.

What the two compounds share

GHRP-6 and GHRP-2 are both six residues long, both contain unnatural amino acid substitutions that slow enzymatic degradation, and both act as agonists at GHS-R1a. Their growth hormone releasing action is synergistic with growth hormone releasing hormone rather than additive, which is one of the more distinctive pharmacological features of the class 4.

That synergy is informative about mechanism. If two agents acting on the same final pathway simply added their effects, you would infer they were doing the same thing through the same route. Synergy suggests they engage different points in the regulatory circuit — which is consistent with one acting at the GHRH receptor and the other at GHS-R1a, with additional effects on hypothalamic somatostatin tone.

Both compounds also share the characteristic that defines this generation of secretagogues and motivated the search for better ones: they do not release growth hormone in isolation. Adrenocorticotropic hormone, and consequently cortisol, rises alongside it, as does prolactin 4. For a research probe intended to isolate growth hormone effects, that is a confound built into the tool.

Where they differ

The potency difference is the more straightforward of the two. GHRP-2 was developed later and was reported to produce growth hormone release at lower concentrations than GHRP-6 in comparable assays 4. As with any cross-study comparison, the reported ratio depends on the species, the assay and the reference used, and the numbers vary between reports.

The appetite difference is more interesting mechanistically. Ghrelin, the endogenous ligand for this receptor, is strongly associated with hunger signalling — it is secreted from the stomach and acts on hypothalamic circuits governing food intake. An agonist at that receptor might therefore be expected to influence appetite, and GHRP-6 in particular has been consistently reported to do so.

Why two agonists at the same receptor should differ in this respect is not fully settled. Possibilities include differences in how readily each compound reaches the relevant hypothalamic sites, differences in the intracellular signalling pathways each preferentially activates at the same receptor, or differences in potency that simply shift where each effect appears relative to the other. The literature does not decisively distinguish these.

The system is larger than growth hormone

This is the point most often lost when these compounds are discussed as growth hormone tools. GHS-R1a is not a pituitary-only receptor, and ghrelin is not a growth-hormone-only hormone. The receptor is expressed in the hypothalamus, and the ghrelin system has documented roles in appetite regulation, gastric motility, glucose handling and cardiovascular function 5.

An agonist at this receptor is therefore engaging a broad physiological system. That is not a criticism of the compounds — it is simply what they are. But it means that describing GHRP-2 or GHRP-6 as a growth hormone releaser captures one output of a receptor with several, and any account that treats the other outputs as incidental is incomplete.

What the human record supports

Both compounds have been administered to humans in research settings, primarily in acute studies characterising the growth hormone response and in work using them as diagnostic stimuli for pituitary function. Those studies establish that the compounds do what their receptor pharmacology predicts: they produce a measurable growth hormone pulse, along with the accompanying corticotropin and prolactin responses.

What the human record does not contain is a substantial body of controlled data on sustained administration. Neither compound completed a development programme that produced an approved product, and the trial infrastructure that would have generated long-term human evidence was therefore never built out.

This leaves a familiar asymmetry. The acute pharmacology is well characterised and the receptor biology is genuinely well understood — this receptor has been studied intensively since 1996 for reasons entirely unrelated to these compounds. The consequences of stimulating it repeatedly over months in humans are not established.

Reading comparisons between them

Why six residues

The length of these compounds is not arbitrary. It is the outcome of a structure-activity programme that tested many variants and converged on hexapeptides because that was where potency and stability were jointly acceptable 2.

Shorter peptides tend to lose the conformational information needed for high-affinity receptor binding. A chain of three or four residues has too few degrees of freedom constrained to reliably present the right shape. Longer peptides are more expensive to synthesise, offer more sites for enzymatic attack, and gain nothing if the additional residues make no receptor contact, which is the same principle that made GHRH truncation work, running in the other direction.

Both compounds also incorporate unnatural residues, including D-configuration amino acids. Proteases are stereospecific: they recognise the L-configuration that biological proteins are built from. Placing a D-residue at a cleavage site leaves the peptide's receptor interaction largely intact while making it substantially harder for the enzyme to act, which is among the oldest and most reliable stabilisation strategies in peptide chemistry.

The result is a compound short enough to synthesise cheaply, long enough to bind well, and modified enough to survive in circulation for a useful period. Those three constraints between them explain most of what these molecules look like.

It is also worth noting what the synergy with growth hormone releasing hormone implies for study design. Because the two signals amplify one another rather than simply summing, the response measured after a secretagogue depends heavily on the prevailing hypothalamic state at that moment. A compound tested during a natural trough will appear to do something different from the same compound tested during a natural peak. This is one reason cross-study comparisons within this family are less informative than they look, and it argues for treating any single reported potency ratio as provisional rather than settled.

• Almost all published comparisons are between separate studies rather than head-to-head within one protocol, so differences in species, assay and timing contribute to the apparent difference.
• Potency and selectivity are separate axes. A more potent compound is not automatically a cleaner one, and the cortisol and prolactin responses are reported for both.
• Acute findings do not establish what happens with repetition, particularly for a receptor with documented desensitisation behaviour.
• The receptor is shared with the endogenous ghrelin system, so effects outside the growth hormone axis are expected rather than surprising.

The most defensible summary is that GHRP-2 and GHRP-6 are closely related tools that opened up an entire area of receptor biology, that their acute endocrine effects are well described, and that they were superseded as research tools by compounds designed to produce a cleaner hormonal response. The scientific legacy of the class is substantial: it led directly to the identification of a receptor and a hormone that turned out to matter far beyond growth hormone.